Sigma-Aldrich, Kings College London Ink Deal on miRNA Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma Life Science today announced a licensing deal with King's College London for the development and commercialization of technology to identify and validate miRNA targets in research and clinical diagnostics.

The technology was developed at the division of cancer studies at King's College. No further details about the technology or terms of the deal were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.